MX2024004213A - Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. - Google Patents

Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.

Info

Publication number
MX2024004213A
MX2024004213A MX2024004213A MX2024004213A MX2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A
Authority
MX
Mexico
Prior art keywords
inhibitors
kras
pi3ka
combinations
treatment
Prior art date
Application number
MX2024004213A
Other languages
English (en)
Spanish (es)
Inventor
James Gail Christensen
Peter Olson
Jill Hallin
Vickie Bowcut
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2024004213A publication Critical patent/MX2024004213A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004213A 2021-10-05 2022-10-04 Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. MX2024004213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252384P 2021-10-05 2021-10-05
PCT/US2022/045619 WO2023059594A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment

Publications (1)

Publication Number Publication Date
MX2024004213A true MX2024004213A (es) 2024-07-29

Family

ID=85803703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004213A MX2024004213A (es) 2021-10-05 2022-10-04 Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.

Country Status (10)

Country Link
US (1) US20240408098A1 (https=)
EP (1) EP4412716A4 (https=)
JP (1) JP2024537139A (https=)
KR (1) KR20240073112A (https=)
CN (1) CN118338904A (https=)
AU (1) AU2022359282A1 (https=)
CA (1) CA3233566A1 (https=)
IL (1) IL311834A (https=)
MX (1) MX2024004213A (https=)
WO (1) WO2023059594A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025080956A1 (en) * 2023-10-12 2025-04-17 Mirati Therapeutics, Inc. Mrtx1133 pharmaceutical compositions
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2014142660A1 (en) 2013-03-12 2014-09-18 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer and kras-mutant colon cancer
AU2019355574A1 (en) 2018-10-05 2021-05-06 Sloan-Kettering Institute For Cancer Research PI3K inhibitors and uses thereof
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US20240139193A1 (en) * 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4225383A4 (en) * 2020-10-08 2024-12-11 Kumquat Biosciences Inc. MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES

Also Published As

Publication number Publication date
KR20240073112A (ko) 2024-05-24
CA3233566A1 (en) 2023-04-13
AU2022359282A1 (en) 2024-04-11
US20240408098A1 (en) 2024-12-12
IL311834A (en) 2024-05-01
EP4412716A1 (en) 2024-08-14
WO2023059594A1 (en) 2023-04-13
EP4412716A4 (en) 2025-08-13
JP2024537139A (ja) 2024-10-10
CN118338904A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2024009727A (es) Terapias de combinacion.
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
EA202190749A1 (ru) Способы комбинированной терапии
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
ZA202304965B (en) Combination therapy for treating cancer
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
MX2020007066A (es) Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.